NA
SNTI icon

NewEdge Advisors’s Senti Biosciences Holdings SNTI Stock Holding History

NewEdge Advisors’s Portfolio SNTI Stock Details SNTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,000
Closed -$9.74K – 4370
2026
Q1 		$9.74K Buy
+12,000
New +$11.6K ﹤0.01% 3409

Other funds holding SNTI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
MVM
Menlo Ventures Management Menlo Park, California $357M AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

NewEdge Advisors's SNTI Position: Q2 2026 in Review

NewEdge Advisors sold out of Senti Biosciences Holdings (SNTI) in Q2 2026, closing a stake of 12,000 shares — an estimated $9.74K sold.

NewEdge Advisors first reported a position in SNTI in Q1 2026 and held it in 1 quarter. The position peaked at $9.74K in Q1 2026. 19 funds tracked by Wall St. Rank hold SNTI as of Q2 2026.

  • NewEdge Advisors reported no remaining Senti Biosciences Holdings position as of Q2 2026 after selling out during the quarter.
  • NewEdge Advisors sold 12,000 Senti Biosciences Holdings shares in Q2 2026, an estimated $9.74K.
  • NewEdge Advisors first reported a position in Senti Biosciences Holdings in Q1 2026 and held it in 1 quarter.
  • NewEdge Advisors's Senti Biosciences Holdings position peaked at $9.74K in Q1 2026.
  • 19 funds tracked by Wall St. Rank held Senti Biosciences Holdings as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.